Daily Market Commentary for March 12, 2014
OXiGENE, Inc. (OXGN-Nasdaq) announced late Tuesday, positive results from a randomized Phase 2 clinical trial evaluating Avastin® (bevacizumab) with or without ZYBRESTAT® (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer.
Read More at:http://www.millennium-traders.com/news/newscommentary.aspx
Thanks for reading
Millennium-Traders.Com
http://www.millennium-traders.com